The purpose of glembatumumab-vedotin is to attach gpNMB and, upon internalization, release MMAE by the breakdown of a valine-citrulline peptide linker that is susceptible to proteases, hence causing microtubule inhibition and tumor cell death. Here, GPNMB is linked to neoplasm.